Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESPA trial: valproic acid + simvastatin with gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma
2024-518710-11-00Phase 2Authorised
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Nov 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial of valproic acid, simvastatin, nab-paclitaxel, gemcitabine, cisplatin and 1 more in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Progression-Free Survival (PFS). Planned start Nov 2024; status: authorised.
02
Drugs
valproic acidsimvastatinnab-paclitaxelgemcitabinecisplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-518710-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518710-11-00.